| Document |
Document Title |
|
WO/2022/028389A1 |
A fused tricyclic derivative as shown in general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, particularly a use as a TLR7/8/9 inhibitor and...
|
|
WO/2022/029096A1 |
The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2022/029704A1 |
The present invention relates to a process for the preparation of a compound of formula (I) and to novel intermediates of the synthesis, wherein X is hydrogen, bromine or iodine; R1 is a protecting group, R2 is hydrogen or a protecting g...
|
|
WO/2022/029068A1 |
The present invention relates to compounds of formula (I), (I), wherein R1, R2, R3, R4 and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the c...
|
|
WO/2022/029069A1 |
The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the co...
|
|
WO/2022/025236A1 |
The present invention provides: a photoelectric conversion element which has excellent sensitivity with respect to light having a wavelength of 500 nm; an imaging element; an optical sensor; and a compound. A photoelectric conversion ele...
|
|
WO/2022/025248A1 |
The compound represented by the following general formula is used as this light-emitting material. Any one of R1, R2, and R4 is a hydrogen atom or deuterium atom, and the remaining thereof are donor groups of which at least one is a carb...
|
|
WO/2022/023447A2 |
The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also r...
|
|
WO/2022/022846A1 |
The present invention relates to a compound of general formula (I) wherein R1-7, Hy, and X are as defined in claim 1. Such compound of formula (I) binds to VDAC1 and is suitable for use in a method for treating diabetes or pre- diabetes ...
|
|
WO/2022/017519A1 |
A quinazoline compound and a pharmaceutically acceptable salt thereof, in particular a compound of formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/018175A1 |
The invention relates to an organic compound, in particular for the application in optoelectronic devices. According to the invention, the organic compound consists of - a first chemical moiety with a structure of formula (I), and - two ...
|
|
WO/2022/018179A1 |
The invention relates to a light emitting organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule consists of - a first chemical moiety with a structure of formula I...
|
|
WO/2022/018182A1 |
The invention relates to a light emitting organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has - one first chemical moiety with a structure of formula I, and ...
|
|
WO/2022/012671A1 |
Crystallines form or amorphous forms of bisdiazabicyclic compounds or salts thereof for the treatment and/or prevention of diseases or disorders related to hepatitis virus, and a preparation method and application thereof are provided. T...
|
|
WO/2022/013136A1 |
The present invention relates to compounds of formula (I) wherein R1, R2, R3a, R3b, R4, Q, Z and Y are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using...
|
|
WO/2022/012509A1 |
A compound as a BTK inhibitor or an HER2 inhibitor, a preparation method therefor, and a use thereof. The compound comprises a structure as shown in formula II or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, or a mix...
|
|
WO/2022/014724A1 |
A compound of the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof has a superior inhibitory activity on cancer cell proliferation.
|
|
WO/2022/012510A1 |
A compound serving as a BTK inhibitor, a preparation method therefor, and a use thereof. The compound has a structure represented by formula I, or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture thereof, or ...
|
|
WO/2022/011318A1 |
This disclosure relates to methods, uses, combinations, pharmaceutical compositions, combinations for use, and pharmaceutical compositions for use useful for treating cognitive impairment associated with central nervous system (CNS) diso...
|
|
WO/2022/009651A1 |
A compound represented by general formula below is useful as a light-emitting material. Ar is a hydrogen atom, an aromatic hydrocarbocyclic group, or a nitrogen atom-containing aromatic heterocyclic group; 1-3 of R1 to R4 are carbazole-9...
|
|
WO/2022/008911A1 |
Benzodiazepine derivatives of formula (Ie) wherein one of R1 and R2 is a benzodiazepinyl-containing group of formula (II) in which R8 is H or halo; the other of R1 and R2 is a group Z selected from H, C3-C6 cycloalkyl, halo, -NHR9, benzy...
|
|
WO/2021/236779A9 |
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-...
|
|
WO/2022/006871A1 |
Disclosed are processes for preparing oligonucleotides. The process comprises: (a) converting a compound of Formula X-1 into a compound of Formula X-2: where R10 is a residue of an oligonucleotide (e.g., a phosphorodiamidate morpholino o...
|
|
WO/2022/008627A2 |
The present invention provides an improved method for the production of lysergic acid diethylamide (LSD) for GMP purposes. Furthermore, the present invention provides novel LSD derivatives of formula (I) as well as their synthesis and pu...
|
|
WO/2022/004812A1 |
Disclosed is a method for producing a perylene dimer compound having imide groups, the method including a step in which a perylene dimer compound represented by formula 3 is reacted with an amine compound represented by formula 30 to yie...
|
|
WO/2022/002097A1 |
The present invention relates to a pyrazolo[1,5-a]pyridine compound as represented by the general formula (I), a preparation method therefor, a pharmaceutical composition, and the use thereof. In the formula, R1, R2, R3, R4, R5, X, Y, an...
|
|
WO/2022/006129A1 |
This invention is directed to compositions including IRAK4 inhibitors useful for the treatment of dermatological disorders or conditions characterized by inflammation. This invention is also directed to methods for treating the dermatolo...
|
|
WO/2022/004473A1 |
The present invention provides: a photoelectric conversion element which has excellent photoelectric conversion efficiency with respect to blue to green light (specifically, light having a wavelength of from 400 nm to 550 nm), and which ...
|
|
WO/2021/262684A1 |
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present d...
|
|
WO/2021/261447A1 |
The present invention addresses a first problem of providing a photoelectric conversion element having high external quantum efficiency and little response variation. The present invention also addresses a second problem of providing an ...
|
|
WO/2021/262763A1 |
The present disclosure relates to novel opioid receptor modulator compounds. Pharmaceutical compositions comprising such buprenorphine analog compound are also disclosed, and the use of such compound in the treatment of visceral hyperalg...
|
|
WO/2021/254005A1 |
An immunosuppressant having the structure of formula (I), and a preparation method therefor and the use thereof. The series of compounds of the present invention can be widely used in the preparation of drugs for preventing and/or treati...
|
|
WO/2021/250541A1 |
Described herein are compounds of Formula I and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compoun...
|
|
WO/2021/252781A1 |
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or d...
|
|
WO/2021/249319A1 |
Provided in the present application are a tricyclic compound, an isomer, pharmaceutically acceptable salt, and pharmaceutical composition thereof and the use thereof, wherein the tricyclic compound has a structure as shown by formula I. ...
|
|
WO/2021/252775A1 |
Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, especially huntingtin protein aggregation, compositions thereof, and methods of their use.
|
|
WO/2021/247717A1 |
The invention relates to solid forms of 2-indolyl imidazo[4,5-D]phenanthroline, methods of their preparation, pharmaceutical compositions thereof and methods of their use.
|
|
WO/2021/244609A1 |
The present invention relates to a compound of formula (I) in which L1, A, X1, X2, X3, R1, R2, R 3, R4, R5, R6, R9, R10, m, and n are as defined in the description, and a stereoisomer, a pharmaceutically acceptable salt, a solvate, or a ...
|
|
WO/2021/239068A1 |
Disclosed herein are heterocyclic compounds that may be used as STING modulators, the process for synthesis and to the use of such compounds in treatment of various diseases including cancers.
|
|
WO/2021/241741A1 |
The present invention provides a photoelectric conversion element having excellent sensitivity, an image sensor, an optical sensor, and a compound. The photoelectric conversion element of the present invention has a conductive film, a ph...
|
|
WO/2021/242581A1 |
This invention provides for compounds of the formula (I): wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and method for the treatment, control or prevention of a parasitic infestation ...
|
|
WO/2021/240337A1 |
The present invention is directed to novel translational inhibitors that bind covalently with eukaryotic initiation factor 4E (eIF4E) and inhibit or modulate the activity of eIF4E, as well as stereoisomers, tautomers and pharmaceutically...
|
|
WO/2021/237038A1 |
Arylsulfonamides of 4-heteroaryl-piperidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such as...
|
|
WO/2021/233800A1 |
The present invention relates to novel ophthalmic devices comprising polymerized compounds comprising a photoactive chromophore, said polymerized compounds, and special monomer compounds being particularly suitable for compositions and o...
|
|
WO/2021/235549A1 |
To provide an exceptional light-emitting material. A compound represented by the general formula is used as a light-emitting material. R is a heteroaryl group bonded with a hydrogen atom, a deuterium atom, an aryl group, or a carbon atom...
|
|
WO/2021/231323A1 |
Described herein are methods of treating cancer in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-
2-yl)-2-methyl-1H-i...
|
|
WO/2021/231653A1 |
Disclosed herein are compounds and combinations of compounds for treating a disease or condition, such as cancer.
|
|
WO/2021/228223A1 |
The present invention relates to a deuterated AKT kinase inhibitor, and in particular to a compound represented by formula I, or pharmaceutically-acceptable salts thereof. The present invention further provides a preparation method, and ...
|
|
WO/2021/231571A1 |
Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.
|
|
WO/2021/228248A1 |
Provided in the present invention is a compound as represented by formula (I) or a tautomer, a stereoisomer, a solvate, a nitrogen oxide, a prodrug, an isotope derivative or a pharmaceutically acceptable salt thereof. The compound exhibi...
|
